Table 1. Patient characteristics, according to receipt of chemotherapy, Stage I-III breast cancer patients, Kaiser Permanente Northern California, 2004-2007.

	Received chemotherapyb						Total
	Yes			No
	N	Column (%)	Row (%)	N	Column (%)	Row (%)	N	Column (%)
Age at diagnosis (years)a
0–39	213	8.0	86.9	32	1.0	13.1	245	4.1
40–49	763	28.6	74.4	263	7.9	25.6	1026	17.1
50–59	927	34.7	55.6	739	22.2	44.4	1666	27.7
60–69	556	20.8	36.8	955	28.6	63.2	1511	25.2
≥70	210	7.9	13.5	1346	40.4	86.5	1556	25.9
Race/Ethnicitya
Non–Hispanic (NH) White	1670	62.6	40.8	2428	72.8	59.2	4098	68.3
NH Black	228	8.5	53.0	202	6.1	47.0	430	7.2
Hispanic	345	12.9	54.2	291	8.7	45.8	636	10.6
NH Asian/Pacific Islander	400	15.0	51.9	370	11.1	48.1	770	12.8
NH American Indian/Alaskan Native, other, or unknown	26	1.0	37.1	44	1.3	62.9	70	1.2
Socio-economic status, quintilesa
Lowest quintile	122	4.6	43.3	160	4.8	56.7	282	4.7
Second quintile	325	12.2	44.9	399	12.0	55.1	724	12.1
Third quintile	499	18.7	43.5	647	19.4	56.5	1146	19.1
Fourth quintile	780	29.2	44.4	977	29.3	55.6	1757	29.3
Highest quintile	943	35.3	45.0	1152	34.5	55.0	2095	34.9
Marital statusa
Single, separated, divorced, widowed	903	33.8	37.6	1501	45.0	62.4	2404	40.0
Married	1745	65.4	49.2	1804	54.1	50.8	3549	59.1
Unknown	21	0.8	41.2	30	0.9	58.8	51	0.8
Tumor Size (cm)a
<1	156	5.8	13.1	1034	31.0	86.9	1190	19.8
1 to <2	888	33.3	38.6	1415	42.4	61.4	2303	38.4
2 to <3	810	30.3	61.3	512	15.4	38.7	1322	22.0
3 to <4	391	14.6	71.0	160	4.8	29.0	551	9.2
4 to <5	219	8.2	77.9	62	1.9	22.1	281	4.7
≥5	165	6.2	74.7	56	1.7	25.3	221	3.7
Microscopic foci, diffuse, or not stated	40	1.5	29.4	96	2.9	70.6	136	2.3
Lymph node involvementa
No nodes	1202	45.0	29.1	2935	88.0	70.9	4137	68.9
Positive nodes	1464	54.9	78.7	397	11.9	21.3	1861	31.0
Unknown	3	0.1	50.0	3	0.1	50.0	6	0.1
Stagea
Stage I	667	25.0	21.1	2501	75.0	78.9	3168	52.8
Stage II	1451	54.4	66.5	732	21.9	33.5	2183	36.4
Stage III	551	20.6	84.4	102	3.1	15.6	653	10.9
Gradea
Grade I (well differentiated)	267	10.0	19.8	1081	32.4	80.2	1348	22.5
Grade II (moderately well differentiated)	1028	38.5	42.0	1419	42.5	58.0	2447	40.8
Grade III (poorly or undifferentiated)	1219	45.7	69.4	537	16.1	30.6	1756	29.2
Grade and differentiation not stated	155	5.8	34.2	298	8.9	65.8	453	7.5
Histologya
Ductal	2002	75.0	46.0	2347	70.4	54.0	4349	72.4
Lobular	510	19.1	42.0	703	21.1	58.0	1213	20.2
Both	157	5.9	35.5	285	8.5	64.5	442	7.4
Estrogen and progesterone receptorsa
Positive (either or both)	1878	70.4	38.5	2997	89.9	61.5	4875	81.2
Negative (both)	778	29.1	71.6	309	9.3	28.4	1087	18.1
Unknown (both)	13	0.5	31.0	29	0.9	69.0	42	0.7
HER2/Neu (HER2)a
Positive	482	18.1	71.3	194	5.8	28.7	676	11.3
Negative	1539	57.7	39.3	2381	71.4	60.7	3920	65.3
Unknown or borderline	648	24.3	46.0	760	22.8	54.0	1408	23.5
Charlson Comorbidity Indexb
0	2232	83.6	48.2	2403	72.1	51.8	4635	77.2
1	338	12.7	35.7	608	18.2	64.3	946	15.8
2	72	2.7	28.0	185	5.5	72.0	257	4.3
≥3	27	1.0	16.3	139	4.2	83.7	166	2.8
Diabetesb
Yes	205	7.7	30.1	475	14.2	69.9	680	11.3
No	2464	92.3	46.3	2860	85.8	53.7	5324	88.7
Neuropathyb
Yes	44	1.6	23.5	143	4.3	76.5	187	3.1
No	2625	98.4	45.1	3192	95.7	54.9	5817	96.9
Heart Diseaseb
Yes	82	3.1	18.9	353	10.6	81.1	435	7.2
No	2587	96.9	46.5	2982	89.4	53.5	5569	92.8
Modified Charlson Comorbidity Indexc
0	2403	90.0	46.1	2813	84.3	53.9	5216	86.9
1	239	9.0	36.5	416	12.5	63.5	655	10.9
2	24	0.9	24.7	73	2.2	75.3	97	1.6
≥3	3	0.1	8.3	33	1.0	91.7	36	0.6
Multiple primary tumors diagnosed within 60 daysa
Yes	44	1.6	44.9	54	1.6	55.1	98	1.6
No	2625	98.4	44.4	3281	98.4	55.6	5906	98.4
Endocrine therapyb, d
Yes	1750	93.2	42.0	2419	80.7	58.0	4169	85.5
No	128	6.8	18.1	578	19.3	81.9	706	14.5
Radiation therapya
Yes	1137	42.6	37.6	1887	56.6	62.4	3024	50.4
No	1532	57.4	51.4	1448	43.4	48.6	2980	49.6
Surgerya
Mastectomy	1326	49.7	56.8	1008	30.2	43.2	2334	38.9
Breast conserving surgery	1300	48.7	36.4	2271	68.1	63.6	3571	59.5
Other or no surgery	43	1.6	43.4	56	1.7	56.6	99	1.6
Anthracycline (doxorubixcin, epirubicin)e
Yes	2477	92.8	100.0				2477	41.3
No	192	7.2	5.4	3335	100.0	94.6	3527	58.7
Taxane (docetaxel, paclitaxel)e
Yes	1659	62.2	100.0				1659	27.6
No	1010	37.8	23.2	3335	100.0	76.8	4345	72.4
Trastuzumabe
Yes	491	18.4	100.0				491	8.2
No	2178	81.6	39.5	3335	100.0	60.5	5513	91.8
Combination chemotherapy within 4 months, among women with ER/PR-negative tumors ≥1 cm in size and age <70 yearsf
Yes	595	92.5	100.0				595	81.3
No	48	7.5	35.0	89	100.0	65.0	137	18.7
Trastuzumab, among women diagnosed in 2006–2007 with HER2-positive tumorsf
Yes	199	88.8	100.0				199	68.4
No	25	11.2	27.2	67	100.0	72.8	92	31.6
Total	2669	100.0	44.5	3335	100.0	55.5	6004	100.0

^aData from the California Cancer Registry

^bData from Kaiser Permanente Northern California

^cThis modified Charlson Comorbidity Index excluded heart disease, diabetes and neuropathy, which were evaluated separately

^dLimited to women with estrogen receptor and/or progesterone receptor-positive breast cancers (N = 4875)

^eAmong women who received chemotherapy

^fMeasure of the American Society of Clinical Oncology Quality Oncology Practice Initiative (ASCO QOPI)